久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Nirsevimab shows promise for long-term RSV protection pharmatimes
    July 31, 2020
    AstraZeneca and Sanofi's nirsevimab has shown a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial
  • US and European regulatory agencies fast track AstraZeneca’s RSV drug pharmaceutical-technology
    February 19, 2019
    AstraZeneca and its division MedImmune have secured fast tract status for their respiratory syncytial virus (RSV) therapeutic, MEDI8897, from both the US and European regulatory authorities....

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service